ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.58
-0.50%
US Tech 100
18,375.20
0.31%
S&P 500
5,306.04
0.02%
US Dollar vs CAD
1.36635
0.11%
Bitcoin
68,617.33
0.48%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Surface Oncology Inc (SURF)

  7. Surface Oncology Inc (SURF) News

SURF

Surface Oncology (SURF)

Surface Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SURF
DateTimeSourceHeadlineSymbolCompany
09/12/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SURFSurface Oncology Inc
09/12/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SURFSurface Oncology Inc
09/08/20233:10PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:09PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:08PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:07PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:06PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:05PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
09/08/20233:04PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SURFSurface Oncology Inc
09/08/20233:03PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SURFSurface Oncology Inc
09/08/20233:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
09/08/20233:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
09/08/20233:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
09/08/20233:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
09/08/20233:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
09/08/20238:21AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SURFSurface Oncology Inc
08/31/20234:18PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SURFSurface Oncology Inc
08/31/20233:01PMGlobeNewswire Inc.Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciencesNASDAQ:SURFSurface Oncology Inc
08/30/20233:34PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SURFSurface Oncology Inc
08/30/20233:32PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SURFSurface Oncology Inc
08/30/20233:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SURFSurface Oncology Inc
08/11/20237:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
08/11/20237:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
08/11/20237:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
08/02/20236:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SURFSurface Oncology Inc
08/02/20236:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SURFSurface Oncology Inc
08/02/20236:00AMGlobeNewswire Inc.Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023NASDAQ:SURFSurface Oncology Inc
07/26/20233:56PMEdgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:SURFSurface Oncology Inc
07/20/20237:00AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SURFSurface Oncology Inc
07/12/20234:08PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SURFSurface Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:SURF

Your Recent History

USOTC
EPAZ
Epazz (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
SAPX
Seven Arts Entertainment (PK)
USOTC
CBIA
Canopus Biopharma (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
FCEL
FuelCell Energy
USOTC
IQST
iQSTEL (QX)
USOTC
HHSE
Hannover House (PK)
NASDAQ
TSLA
Tesla
NASDAQ
FFIE
Faraday Future Intellige...
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved